Ruben J. Boado

Fundador en ArmaGen, Inc. .

Consumer Services

Health Services

Perfil

Ruben J.
Boado is the founder of ArmaGen, Inc. which was founded in 2004.
He held the title of Vice President-Research & Development.
Dr. Boado's former job was as a Professor at the University of California, Los Angeles.
Dr. Boado received a doctorate degree from Universidad de Buenos Aires.

Cargos activos de Ruben J. Boado

Empresas	Cargo	Inicio
ArmaGen, Inc. ArmaGen, Inc. Hospital/Nursing ManagementHealth Services ArmaGen, Inc. engages in operation of a clinical stage biotechnology company focused on developing revolutionary therapies for severe neurological disorders. Its products include AGT-110-Brain-penetrating biologic tumor necrosis factor inhibitor (TNFI) for Alzheimer's disease, AGT-115-Brain-penetrating erythropoietin (EPO) for stroke, AGT-160-Brain penetrating anti-amyloid antibody (AAA) for Alzheimer's disease and AGT-181-Brain-penetrating iduronidase (IDUA) for Mucopolysaccharidosis (MPS) Type I (Hurler's syndrome). The company was founded by William M. Pardridge and Ruben J. Boado in 2003 and is headquartered in San Diego, CA.	Fundador	01/01/2004

Todos los cargos activos de Ruben J. Boado

Antiguos cargos conocidos de Ruben J. Boado.

Empresas	Cargo	Fin
University of California, Los Angeles	Corporate Officer/Principal	-

Ver el detalle de la experiencia de Ruben J. Boado.

Formación de Ruben J. Boado.

Universidad de Buenos Aires

Doctorate Degree

Experiencias
Funciones ocupadas

Activas

Inactivas

Empresas cotizadas

Empresas privadas

Ver el detalle de la experiencia de Ruben J. Boado.

Relaciones

Relaciones de 1er grado

Empresas vinculadas al 1er grado

Hombre

Mujer

Administradores

Ejecutivos

Consultar la red personal

Empresas relacionadas

Empresas privadas	1
ArmaGen, Inc. ArmaGen, Inc. Hospital/Nursing ManagementHealth Services ArmaGen, Inc. engages in operation of a clinical stage biotechnology company focused on developing revolutionary therapies for severe neurological disorders. Its products include AGT-110-Brain-penetrating biologic tumor necrosis factor inhibitor (TNFI) for Alzheimer's disease, AGT-115-Brain-penetrating erythropoietin (EPO) for stroke, AGT-160-Brain penetrating anti-amyloid antibody (AAA) for Alzheimer's disease and AGT-181-Brain-penetrating iduronidase (IDUA) for Mucopolysaccharidosis (MPS) Type I (Hurler's syndrome). The company was founded by William M. Pardridge and Ruben J. Boado in 2003 and is headquartered in San Diego, CA.	Health Services